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Effective gene therapy depends on the efficient transfer of therapeutic genes to target cells. None of the current technologies,
however, satisfy all of the requirements necessary for gene therapy, because the plasma and nuclear membranes of mammalian cells
are tight barriers against gene transfer using synthetic delivery systems. The protein transduction domain (PTD) of human
immunodeficiency virus type 1 (HIV-1) Tat protein greatly facilitates protein transfer via membrane destabilisation. We synthesised
polylysine peptides containing Tat PTD (TAT-pK), or other sequences, and investigated their potential as agents for gene transfer.
The synthesised polypeptide TAT-pK retains DNA binding function and mediates delivery of a reporter gene to cultured cells. RGD
motif binds with low affinity to alpha integrins which induce cell activation. Two control polypeptides, GGG-pK and RGD-pK, were
synthesised and tested, but their gene transfer abilities were weaker than those of TAT-pK. TAT-pK-mediated gene transfer was
enhanced in the presence of chloroquine or ammonium chloride, to a greater extent than that of cationic lipid-mediated gene
transfer in most cancer cell lines tested. These data suggest that TAT-pK may be a potent candidate delivery vehicle that promotes
gene transfer, dependent on the endocytic pathway. We conclude that the TAT-pK/DNA complex is useful as a minimal unit to
package therapeutic genes and to transduce them into mammalian cells.
British Journal of Cancer (2004) 90, 1252–1258. doi:10.1038/sj.bjc.6601680 www.bjcancer.com
Published online 24 February 2004
& 2004 Cancer Research UK
Keywords: HIV Tat protein; poly-lysine; DNA delivery
                                                   
Gene therapy for cancer has been developed and a number of
clinical therapeutic protocols are now being investigated. Vectors
based on various viruses are useful for delivering therapeutic genes
into primary cells in vitro and have also been applied in a number
of gene therapy trials with humans. Viruses have some disadvan-
tages as tools for medical application, however, with many
elements of their biology yet to be elucidated. The utility of viral
vectors for gene therapy is limited by DNA carrying capacity,
difficulty in reliable and cost-effective manufacturing, and by
immunogenicity and other safety concerns. One goal of cancer
gene therapy is the development of gene delivery tools with
lowered immunogenicity. While the construction of some viral
vectors with reduced immunogenicity have been reported (Fisher
et al, 1996; Haecker et al, 1996; Kochanek et al, 1996; Kumar-Singh
and Chamberlain, 1996; Morral et al, 1999), preparation of these
vectors is difficult because the virus is composed of several kinds
of large molecules.
Two elements are necessary to efficiently express foreign genes
in cells: passage of DNA across the cell membrane and transport
into the nucleus (Colin et al, 2000). From this point of view,
recombinant viral vectors have a great advantage by depending on
their intrinsic machinery for infection. Basic peptides derived from
human immunodeficiency virus type 1 (HIV-1) Tat protein and
Drosophila Antennapedia protein have been reported to translo-
cate through the cell membrane and to carry exogenous molecules
into the cytoplasm and nucleus (Derossi et al, 1994, 1996; Vive `s
et al, 1997; Nagahara et al, 1998; Schwartz et al, 1999; Dostman
et al, 2000). HIV-1 Tat is an 86 amino-acid protein, and aa 47–57
of Tat (YGRKKRRQRRR) possess a high net positive charge at
physiological pH, with nine of its 11 amino acids being either
arginine or lysine. Fusion of several proteins and this 11 aa region
of Tat protein enables the delivery of proteins into cells. Thus, this
11 aa region is considered a protein transduction domain (PTD). A
119-kDa protein, b-galactosidase, genetically fused to HIV-1 Tat
PTD, was successfully carried into various mouse tissues,
including the brain, following intraperitoneal injection (Nagahara
et al, 1998).
Molecular conjugates of poly-lysine with natural or artificial
ligands utilise the DNA-binding and -condensing properties of
poly-lysine to mediate interaction with DNA (Wagner et al, 1991;
Perales et al, 1994). Upon formation of a DNA-poly-lysine-ligand
complex (polyplex (Felgner et al, 1997)), gene transfer is facilitated
via receptor-mediated endocytosis.
In this study, we investigated the potential of a poly-lysine fused
Tat PTD (TAT-pK) as a gene delivery agent. We demonstrate that
TAT-pK combines with DNAs and efficiently transports them into
several human cell lines.
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Reagents
Reagents were obtained from the following sources: chloroquine
and ammonium chloride from WAKO Pure Chemical Industries,
Ltd. (Osaka, Japan); 2,3-dioleyloxy-N-[2-(sperminecarboxami-
do)ethyl]-N00N-dimethyl-1-propanaminium trifluoroacetate
(DOSPA)/dioleoyl phosphatidylethanolamine (DOPE) (LipofectA-
MINEt) from Life Technologies, a division of Invitrogen
(Rockville, MD, USA).
Cell lines
The human embryonic kidney cell line HEK 293 was obtained from
CLONTECH Laboratories. Human pancreatic carcinoma cell lines
PCI10, PCI19, PCI35, and PCI43 were generously provided by Dr
Yoshiki (Hokkaido University, Japan). Human oesophageal
squamous cell carcinoma cell lines TE2, TE5, TE8, and TE13 were
provided by Dr Nishihira (University of Tohoku, Japan). These cell
lines were cultured in Dulbecco’s modified Eagle’s medium
(DMEM; GIBCO, Rockville, MD, USA) with 2mML -glutamine,
supplemented with 10% heat-inactivated foetal calf serum (FCS), at
5% CO2. Human lung carcinoma cell lines A549, RERF-LC-MS,
and PC3 were obtained from the Japanese Cancer Research
Resources Bank (Tokyo, Japan) and NCI-H226 was obtained from
American Type Culture Collection (Manassas, VA, USA). They
were maintained in RPMI medium (GIBCO) with 10% FCS.
Polypeptides synthesis
Three pKs (TAT-pK, RGD-pK, GGG-pK) and TAT were supplied
by Hokkaido System Science Co.,. Ltd. (Sapporo, Japan). They
were chemically synthesised by solid-phase methods, using Fmoc
(9-fluorenylmethyloxycarbonyl) with a Pioneert Peptide Synthesis
System (Applied Biosystems, CA, USA). Primary structures of the
polypeptides were shown in Table 1.
Plasmid DNAs
The expression plasmid for enhanced green fluorescent protein
(EGFP) (CLONTECH Laboratories, CA, USA) was constructed by
inserting the cDNA into pcDNA3.1þ to produce pcDNA-EGFP.
The expression vector for firefly luciferase pGL3 was obtained
from Promega Corp (Madison, WI, USA).
Agarose gel electrophoresis of DNA-peptides complex
For the agarose gel electrophoresis assay, 0.5mg of DNA (lambda
DNA/HindIII digest) and peptides were mixed and incubated for
10min at room temperature. The samples were loaded on a 1%
agarose gel containing 0.5mgml
 1 of ethidium bromide and run
for 30min at 100V in 1 TBE buffer.
Transfection conditions
A standard protocol for gene transfer into cultured cells was
followed. Cells were seeded at 2 10
4–1 10
5cellswell
 1 in tissue
culture plates, and cultured for 6h. The cells were washed once
with serum-free medium and incubated with medium containing
DNA, DNA-peptides complex, or DNA complexed with cationic
lipids (DOSPA/DOPE) for 8h at 371C. The cells were cultured for
48h in medium with 10% FCS before assaying for the expression of
reporter genes. DNAs were complexed with cationic lipids,
according to the procedures recommended by the suppliers.
Luciferase assay and UV microscopy
Luciferase activity was evaluated using the Luciferase Assay
System (Promega) and relative light units (RLU) were measured
with Mini Lumat LB 9506 (BERTHOLD, Germany). RLUs are
shown as averages with standard deviations. GFP and FITC were
detected with fluorescence microscopy (Olympus Optical Co. Ltd.,
Japan) using a GFPA cube. The cell nucleus was localised with
fluorescence microscopy, using the fluorescent DNA binding dye,
Hoechst 33342, and a WU cube (Olympus Optical Co. Ltd.). FITC
labelled DNA fragments were prepared by phosphoramidite
synthesis and purified by RP-HPLC purification.
WST-8 assay
Cytotoxicity of peptides was investigated using WST-8 assay.
HEK293 cells were seeded in 96-well tissue culture plate at a
density of 2 10
4 cells per well and incubated at 371C for 72h in
fresh medium containing various peptides at a concentration of
10–320mgml
 1. After incubation, 10ml of 2-(2-methoxy-4-nitro-
phenyl)-3-(4-nitrophenyl)-5-(2,4-disulphophenyl)-2H-tetrazolium
(WST-8; Wako Pure Chemical Industries, Ltd, Japan) were added
to each well. After 4h of incubation, the optical density was read
on a microplate autoreader (SPECTRAmax
s 190; Molecular
Devices Corp, Sunnyvale, CA, USA) using a test wavelength of
490nm and a reference wavelength of 620nm.
FACS analysis
Where indicated, 10000 events were counted on a Becton
Dickinson FACScan analyzer (Becton Dickinson, Franklin Lakes,
NJ, USA) using a 15mW air-cooled argon laser set at 488nm, and
recorded with a 530nm emission filter in the FL1 emission
channel. Cell populations are represented on a FACS histogram
plotting FITC intensity on a logarithmic scale against cell number.
Fluorescence intensity of cell populations is indicated by a shift to
the right of the histogram plots of treated cells. Fluorescence
enhancement was determined by obtaining the number of gated
fluorescent events for untreated and treated cells.
RESULTS
DNA mobility shift analyses of pKs using agarose gel
electrophorase
The pK tracts should impart DNA binding function to the fusion
protein, by interacting with the negatively charged phosphate
backbone of nucleic acids. To determine DNA binding ability,
increasing concentrations of peptides were incubated with
constant amounts of DNA marker (l/HindIII), and the
resulting effects on DNA mobility were analysed on agarose
gels (Figure 1). At concentrations where peptides completely
bind and thus neutralise the DNA, it appears immobilised on
the gel. The DNA was immobilised with peptides at a protein-to-
DNA (ww
 1) ratio of 1. These results show that peptides can bind
DNA. Furthermore, excess amounts of peptides did not induce the
DNA to migrate in the opposite direction from the positive
electrode.
Table 1 Primary structures of synthesised polypeptides
Peptides Sequences
TAT-pK NH2–YGRKKRRQRRR-GGG-KKKKKKKKKKKKKKK –COOH
RGD-pK NH2–AIRGDTFATGAS-GGG-KKKKKKKKKKKKKKK –COOH
GGG-pK NH2–GGG-KKKKKKKKKKKKKKK –COOH
TAT NH2–YGRKKRRQRRR-GGG –COOH
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various peptides
We examined the efficiency of peptide-mediated gene transfer by
evaluating the expression of the complexed EGFP gene. Under
standard transfection conditions, we detected strong EGFP
expression in approximately 5% of HEK 293 cells treated with
the TAT-pK/pcDNA-EGFP complex. In cells treated with the
GGG-pK/ or RGD-pK/pcDNA-EGFP complex, however, EGFP
expression was detected in less than 1% of cells (Figure 2A). The
number of cells expressing EGFP increased in proportion to the
dose of pKs/DNA complex (figure not shown). In this study,
the RGD-pK/DNA complex was also introduced into cells in a
dose-dependent manner, but there was no difference in the
transduction efficiency of RGD-pK and of GGG-pK. On the other
hand, DNA complexed with TAT-pK was efficiently introduced,
even at lower doses. The transduction efficiency of TAT peptide
without a sequence of poly-lysine was lower than those of pKs
(Figure 2B).
Cell-binding activities evaluated by FACScan
To investigate the reason for the high efficiency of TAT-pK-
mediated gene transfer, cell-binding activity of pK/DNA complexes
using FITC-labelled DNA was assessed (Figure 3A-H). There was
scarcely any complex bound to cells with GGG-pK (Figure 3A) and
RGD-pK (Figure 3B), and the amount of complex bound to cells
did not increase, even 6h after incubation (data not shown). TAT-
pK/DNA complex, however, bound to almost all cells 60min after
incubation (Figure 3C). The difference in binding activity between
TAT-pK and other pKs should be reflected in the DNA
transduction efficiency. Interestingly, treatment with a small
quantity of TAT-pK/DNA complex rarely led to cell binding
(Figure 3D), and less than 0.1% of cells expressed EGFP when
exposed to the equivalent quantity of TAT-pK/pcDNA-EGFP (data
not shown). Most of the TAT-pK/DNA complex binds to the cells
10–30min after incubation (Figure 3E and F). Tat-(48–60)
has been reported to enter cells extremely rapidly, reaching
the nucleus within 5min (Futaki et al, 2001). Similarly, in our
analysis, binding activity was observed immediately after
incubation, and 1h after incubation, FITC emission was detected
in the nucleus (Figure 3I). No FITC emission was observed in
cells exposed to the other pK/DNA complexes (data not shown).
On the other hand, a four-fold excess of peptides, for neutralisa-
tion of the electrical charge, was required for high affinity (Figure
3G and H). A large number of peptides appear to require the
complex to remain stably on the cell membrane or in the
cytoplasm.
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Figure 1 DNA mobility shift analyses of pKs. Synthesised pKs bind to
plasmid DNA electrically. Three pKs were preincubated with 0.5mgo fl/
HindIII DNA marker. The plasmid DNA was electrophoresed alone or
after preincubation with a given concentration (0.05–5mg) of polypeptides.
All plasmids were immobilised with pKs at a protein-to-DNA (ww
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ratio of 1.
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Figure 2 Induction of marker gene expression by various pKs. (A) In situ
detection of pK-mediated GFP gene expression in HEK 293 cells. Cells
were seeded in 12-well tissue culture plates at a density of
5 10
4cellswell
 1. The cells were treated with pK/pcDNA-EGFP complex
(12mg of pKs and 3mg of DNA) as described under Materials and Methods.
After 8h, medium with 10% FCS was added, and the cells were grown for
another 48h before fluorescent microscopic observation. (B) Induction of
peptide-mediated luciferase gene expression. Cells were seeded in six-well
tissue culture plates at a density of 1 10
5cellswell
 1. The cells were
treated with peptide/pGL3-promoter complex (5mg of DNA). After 8h,
medium with 10% FCS was added, and the cells were grown for another
48h before they were harvested for analysis. Luciferase activity was
evaluated using the Luciferase Assay System (Promega) and estimated in
average relative light units (RLU) with standard deviations.
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The cytotoxicity of the three pKs was investigated after incubating
293 cells with peptide concentrations up to 320mgml
 1 for 72h.
The cytotoxicity of TAT-pK and of RGD-pK were almost equal,
while that of GGG-pK was slight (Figure 4).
Characterisation of TAT-pK-mediated gene transfer in
HEK 293 cells
TAT-pK-mediated EGFP expression was dramatically improved in
the presence of 100mM chloroquine (Figure 5A). Efficiency of TAT-
pK-mediated luciferase expression was also elevated dose-depen-
dently, but exposure to excess amounts of agent reduced the
luciferase activity (Figure 5B). Moreover, as TAT-pK contains a
GRKKR nuclear localisation signal within its sequence, we thought
it would be advantageous for cellular gene expression. These
functions are similar to those of viral vectors that actively bind to
the cell surface via high-affinity ligands, and transport their DNA
into the nucleus by endocytosis. Thus, TAT-pK/DNA complexes
possess the necessary elements for transfection as a small particle,
although the efficiency is lower than that of adenoviral vectors.
When we compared the efficiency of TAT-pK-mediated gene
transfer with that mediated by cationic lipids (DOSPA/DOPA), we
found that TAT-pK can induce higher levels of luciferase activity in
the presence of chloroquine, but not in its absence (Figure 5B). The
cytotoxicity of ammonium chloride or chloroquine was investi-
gated (Figure 5C). Both of ammonium chloride and chloroquine
showed cytotoxicity at a higher concentration. There were no
cytotoxic effects with TAT-pK.
TAT-pK-mediated transduction efficiency in various
human cancer cell lines
To utilise TAT-pK for various purposes, we investigated the
efficiency of TAT-pK-mediated luciferase gene transfer using
several human cancer cell lines that tend to accept gene transfer
with low efficiency (Figure 6). The TAT-pK complex was
successfully introduced into almost all cell lines at superior levels
to DOSPA/DOPA, in the presence of chloroquine.
DISCUSSION
In order to be utilised for gene therapy, gene delivery systems
require convenience and safety. Even transporting a single DNA
encoding a small protein needs a vector construct. Moreover, the
vector has longer DNA and ‘the shell’ that wraps it. Because large
vectors may have adverse effects, our aim was to construct the
smallest possible unit permitting efficient and safe transfection of
DNA into mammalian cells. Cationic polypeptides, such as poly-
arginine and poly-lysine, have been reported to bind DNA, form
complexes with DNA, and introduce themselves into cells (Wagner
et al, 1991; Perales et al, 1994; Felgner et al, 1997; Futaki et al, 2001;
Suzuki et al, 2002). Their efficiency for practical applications to
gene therapy, however, remains untested. In the present study, we
fused the Tat PTD to poly-lysine in order to improve the efficiency
of DNA delivery.
As the pancreatic cancer cell line PCI35 has poor DNA
transfection efficiency with cationic liposomes, we investigated
0
20
40
60
80
100
100 104 103 102 101 0
20
40
60
80
100
100 104 103 102 101
0
20
40
60
80
100
100 104 103 102 101 0
20
40
60
80
100
100 104 103 102 101
0
20
40
60
80
100
100 104 103 102 101 0
20
40
60
80
100
100 104 103 102 101
0
20
40
60
80
100
100 104 103 102 101 0
20
40
60
80
100
100 104 103 102 101
AB
CD
EF
GH
I
GGG–pK/DNA
4:1, 60 min
RGD–pK/DNA
4:1, 60 min
TAT–pK/DNA
4:1, 60 min
TAT–pK/DNA
4:1, 60 min
TAT–pK/DNA
4:1, 10 min
TAT–pK/DNA
4:1, 30 min
TAT–pK/DNA
1:1, 60 min
TAT–pK/DNA
2:1, 60 min
(0.2µg DNA)
Figure 3 Cell binding activity of pK/DNA complex. HEK 293 cells were
grown on 12-well dishes. Peptides and FITC-labelled-DNA were incubated
together at the indicated ratios, at room temperature for 5min in 1ml of
serum-free DMEM, and then added to cell monolayers. Cells were exposed
to mixtures (2mg of DNA) for 60min at 371C, 5% CO2 (A–C). Cells
exposed to mixtures containing 0.8mg of TAT-pK and 0.2mg of DNA for
60min (D), 8mg of TAT-pK and 2mg of DNA for 10min (E) and 30min
(F), indicated ratios of TAT-pK and 2mg of DNA for 60min (G, H). In situ
detection of TAT-pK/FITC-labelled-DNA complexes (I). Cells were
exposed to mixtures containing 8mg of TAT-pK and 2mg of DNA for
2h and FITC was detected with fluorescent microscopy as described under
Materials and Methods.
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Figure 4 Cytotoxicity of polypeptides on HEK 293 cells. Cells were
seeded into 96-well plates and incubated at 371C for 72h in fresh medium
containing a given concentration of various polypeptides. Absorbance was
measured by the WST-8 assay, as described under Materials and Methods.
Each end point represents the mean7s.d.
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Initially, a recombinant Histidine6-tagged TAT-pK (H6-TAT-pK)
construct was produced in E. coli strain BL21(DE3), carrying the
pLysS plasmid (One Shott; Invitrogen Corp., Carlsbad, CA, USA)
to control leak-through expression and to allow subsequent cell
lysis by freeze thawing. This construct was purified using a
HiTrapt column (Amersham Pharmacia Biotech., Buckingham-
shire, UK) and the A ¨KTA primet system (Amersham Pharmacia
Biotech), and a standard protocol for protein production was
followed. The H6-TAT-pK/DNA complex was successfully intro-
duced into PCI35 cells and EGFP expression was detected. The
efficiency of transfection, however, was not better than with
lipofection (data not shown). Subsequently, in order to elucidate
the mechanism for TAT-pK-mediated gene transfer and to
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Figure 5 Characterisation of TAT-pK-mediated gene transfer in HEK 293
cells. (A) Enhancement of TAT-pK-mediated GFP gene expression in HEK
293 cells. Cells were seeded in 24-well tissue culture plates at a density of
2 10
4cellswell
 1. The cells were treated with 1ml fresh medium
containing TAT-pK/pcDNA-EGFP complex (4mg of peptide and 1mgo f
DNA) in the absence (left) or the presence of 100mM chloroquine (right).
EGFP expression was detected with fluorescent microscopy as described
under Materials and Methods. (B) Comparison of transfection activity of
DOSPA/DOPE/DNA complex with TAT-pK/DNA complex and effects of
ammonium chloride or chloroquine on TAT-pK-mediated gene transfer.
HEK 293 cells (5 10
4well
 1) were seeded into 12-well tissue culture
plates. The cells were treated with DOSPA/DOPE/DNA complex (2mlo f
DOSPA/DOPA and 1mg of DNA, open bar), according to the procedures
recommended by the suppliers, or with TAT-pK/DNA complex (4mgo f
peptide and 1mg of DNA) as described under Materials and Methods. The
cells with TAT-pK/DNA complex were incubated for 48h in the absence
(filled bar) or presence (grey bars) of ammonium chloride (25, 50, 100, and
200mM) or chloroquine (25, 50, 100, and 200mM). After incubation, cells
were harvested and luciferase activity was evaluated. The luciferase activities
were averaged from the results of duplicate experiments and are presented
relative to the control value, indicated with the filled bar. (C) Cytotoxicity of
ammonium chloride or chloroquine on HEK293 cells. Cells were seeded
into 96-well plates and incubated at 371C for 48h in fresh medium
containing a given concentration of ammonium chloride (left) or chloroquine
(right) with (filled) or without (open) 20mgml
 1 TAT-pK. After incubation,
absorbance was measured by the WST-8 assay, as described under
Materials and Methods. Each end point represents the mean 7 s.d.
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Figure 6 Transduction efficiency of DOSPA/DOPE or TAT-pK with
chloroquine in various human cancer cell lines. Cells (5 10
4) were
incubated with 1ml medium containing pGL3-promoter DNA (1mg)
complexed with DOSPA/DOPA (open bars) or with TAT-pK in the
presence of 50mM chloroquine (grey bars) or 100mM chloroquine (filled
bars) and grown as described under Materials and Methods. After 48h
incubation, cells were harvested and luciferase activity was measured. Each
end point represents the mean7s.d. RLU, relative light units.
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tag, as well as two control polypeptides GGG-pK and RGD-pK. The
adenoviral RGD (Arg-Gly-Asp) motif AIRGDTFATGAS was fused
to pK to compare the transfection efficiency with that of TAT-pK,
because interaction of the RGD motif in the adenoviral penton
base with cell membrane integrins is required to induce or trigger
endocytosis (Wickham et al, 1993).
We anticipated that the cytotoxicity of TAT-pK would be
stronger than that of RGD-pK, but interestingly, this was not the
case. Actually, as cells would not be exposed to high concentra-
tions for a prolonged time, toxicity is not likely to be a serious
concern. No toxicity was observed, even at the highest doses
examined for DNA transduction.
Most nonviral vehicles deliver their genes passively, relying on
uptake into vesicular compartments by endocytosis, thus we
examined the effects of ammonium chloride or chloroquine on
transduction. Ammonium chloride is a weak acidotropic base.
Chloroquine elevates the pH of vesicular compartments (Cotten
et al, 1990), and either stimulates or inhibits the efficiency of
endocytosis-mediated gene transfer, depending on the delivery
vehicle. We found that TAT-pK-mediated gene transfer is affected
by either of these agents, suggesting that transduction relies on the
endocytic pathway. These results are similar to past reports
showing that gene transfer via receptor-mediated endocytosis
(Cotten et al, 1990) or mediated by DEAE-dextran (Luthman
and Magnusson, 1983) is markedly enhanced with endosomo-
trophic agents, such as chloroquine. However, our data contradict
other studies on TAT-peptide-mediated protein transduction
(Mann and Frankel, 1991; Derossi et al, 1996; Vive `s et al, 1997;
Elliott and O’Hare, 1997) and TAT-phage-mediated gene
transfer (Eguchi et al, 2001) that do not depend on endosomo-
trophic reagents. The mechanism of action of Tat-(48–60) peptide
and the full-length Tat protein may not be the same (Liu et al,
2000). Rather, TAT-pK-mediated gene transfer seems to share
features of both systems, operating by both an energy-dependent
endocytic pathway and an independent pathway. These dual
mechanisms may account for the high efficiency of DNA
transduction. In short, the Tat PTD anchors the TAT-pK/DNA
complex to the cell surface within a few minutes by membrane
destabilisation, and then the complex crosses the cell membrane
by endocytosis.
The conditions suitable for gene transfer differed for each cell
line. As PBS or RPMI medium reduce the efficiency of TAT-pK-
mediated gene transfer (data not shown), we used sterilised water
for diluting pKs and only used DMEM in transfection. Transduc-
tion efficiency of TAT-pK was easily influenced by several factors,
such as pH or temperature of medium, preincubation period, and
quantity of DNA (data not shown). Moreover, the fold absorptions
were decreased at high concentrations of chloroquine because of
its cytotoxicity.
Several Tat PTD fused proteins have been reported as potential
therapeutic strategies for cancer (Mann and Frankel, 1991; Derossi
et al, 1996; Elliott and O’Hare, 1997; Vive `s et al, 1997), but the
quantity of protein transduced into tissues would be lower than
that from administration of vector DNA. Moreover, selectivity and
transduction efficiency are very important factors in order to apply
gene therapy for cancer patients. Although we have not achieved
targeting transduction for cancer cells by using TAT-pK, it may be
easily modified to target cancerous, but not normal cells, since
TAT-pK is much smaller than the capsid proteins of viral vectors.
Also immunogenicity by TAT-pK should be investigated, but we
do not think it higher than that of viral vectors because of its size.
We have started in vivo experiments to assess these factors and to
improve them.
In conclusion, although there is need for further improvement,
TAT-pK is a candidate for a new DNA transfection system. Many
problems still exist in clinical trials using viral vector-mediated
gene therapy, therefore the development of artificial viral vector
systems is urgently needed. TAT-pK is likely a minimal unit to
efficiently package therapeutic genes and transduce them into
mammalian cells.
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